{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:57:30Z","timestamp":1784613450342,"version":"3.55.0"},"reference-count":33,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2020,10,9]]},"DOI":"10.1253\/circrep.cr-20-0041","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T22:07:11Z","timestamp":1600121231000},"page":"565-575","source":"Crossref","is-referenced-by-count":20,"title":["Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients With Compensated Heart Failure Complicated by Diabetes"],"prefix":"10.1253","volume":"2","author":[{"given":"Akihiro","family":"Shirakabe","sequence":"first","affiliation":[{"name":"Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Kiuchi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Inami","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takayasu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Toho Kamagaya Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hasegawa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kanamachi Daiichi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Okajima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniya","family":"Asai","sequence":"additional","affiliation":[{"name":"Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. <i>Eur J Heart Fail<\/i> 2015; 17: 884\u2013892.","DOI":"10.1002\/ejhf.319"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. <i>Circ J<\/i> 2013; 77: 2209\u20132217.","DOI":"10.1253\/circj.CJ-13-0971"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shirakabe A, Hata N, Yamamoto M, Kobayashi N, Shinada T, Tomita K, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. <i>Circ J<\/i> 2014; 78: 911\u2013921.","DOI":"10.1253\/circj.CJ-13-1255"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med<\/i> 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med<\/i> 2017; 377: 2097\u20132099 [Letter].","DOI":"10.1056\/NEJMc1712572"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. <i>JACC Basic Transl Sci<\/i> 2017; 2: 347\u2013354.","DOI":"10.1016\/j.jacbts.2017.07.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: Rationale for and design of the EMPEROR-Reduced trial. <i>Eur J Heart Fail<\/i> 2019; 21: 1270\u20131278.","DOI":"10.1002\/ejhf.1536"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, et al. Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF). <i>Trials<\/i> 2019; 20: 374.","DOI":"10.1186\/s13063-019-3474-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Seo Y, Yamamoto M, Machino-Ohtsuka T, Ishizu T, Aonuma K. Effects and safety of sodium glucose cotransporter 2 inhibitors in diabetes patients with drug-refractory advanced heart failure. <i>Circ J<\/i> 2018; 82: 1959\u20131962.","DOI":"10.1253\/circj.CJ-18-0171"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nunez J, Palau P, Dominguez E, Mollar A, Nunez E, Ramon JM, et al. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. <i>Clin Cardiol<\/i> 2018; 41: 476\u2013480.","DOI":"10.1002\/clc.22899"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, et al. Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality. <i>Circulation<\/i> 2019; 139: 1458\u20131460.","DOI":"10.1161\/CIRCULATIONAHA.118.038339"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wojcik C, Warden BA. Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors. <i>Curr Cardiol Rep<\/i> 2019; 21: 130.","DOI":"10.1007\/s11886-019-1219-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Lancet Diabetes Endocrinol<\/i> 2019; 7: 845\u2013854.","DOI":"10.1016\/S2213-8587(19)30256-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. <i>Circulation<\/i> 2019; 139: 1985\u20131987.","DOI":"10.1161\/CIRCULATIONAHA.118.038881"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al; on behalf of the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. <i>Circ J<\/i> 2019; 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>Eur J Heart Fail<\/i> 2016; 18: 891\u2013975.","DOI":"10.1002\/ejhf.592"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. <i>Circulation<\/i> 2016; 134: 752\u2013772.","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. <i>Diabetologia<\/i> 2018; 61: 2108\u20132117.","DOI":"10.1007\/s00125-018-4670-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. <i>Eur J Heart Fail<\/i> 2011; 13: 846\u2013851.","DOI":"10.1093\/eurjhf\/hfr087"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shirakabe A, Hata N, Kobayashi N, Okazaki H, Matsushita M, Shibata Y, et al. Clinical usefulness of urinary liver fatty acid-binding protein excretion for predicting acute kidney injury during the first 7 days and the short-term prognosis in acute heart failure patients with non-chronic kidney disease. <i>Cardiorenal Med<\/i> 2017; 7: 301\u2013315.","DOI":"10.1159\/000477825"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yokoyama T, Kamijo-Ikemori A, Sugaya T, Hoshino S, Yasuda T, Kimura K. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. <i>Am J Pathol<\/i> 2009; 174: 2096\u20132106.","DOI":"10.2353\/ajpath.2009.080780"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Veerkamp JH, Peeters RA, Maatman RG. Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. <i>Biochim Biophys Acta<\/i> 1991; 1081: 1\u201324.","DOI":"10.1016\/0005-2760(91)90244-C"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Jungbauer CG, Birner C, Jung B, Buchner S, Lubnow M, von Bary C, et al. Kidney injury molecule-1 and <i>N<\/i>-acetyl-beta-D-glucosaminidase in chronic heart failure: Possible biomarkers of cardiorenal syndrome. <i>Eur J Heart Fail<\/i> 2011; 13: 1104\u20131110.","DOI":"10.1093\/eurjhf\/hfr102"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, et al. Tubular damage and worsening renal function in chronic heart failure. <i>JACC Heart Fail<\/i> 2013; 1: 417\u2013424.","DOI":"10.1016\/j.jchf.2013.05.007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Brankovic M, Akkerhuis KM, Hoorn EJ, van Boven N, van den Berge JC, Constantinescu A, et al. Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bio-SHiFT study). <i>Clin Cardiol<\/i> 2020; 43: 630\u2013638.","DOI":"10.1002\/clc.23359"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. <i>Kidney Int<\/i> 2008; 73: 863\u2013869.","DOI":"10.1038\/sj.ki.5002715"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. <i>J Am Soc Nephrol<\/i> 2017; 28: 368\u2013375.","DOI":"10.1681\/ASN.2016030278"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. <i>N Engl J Med<\/i> 2016; 375: 323\u2013334.","DOI":"10.1056\/NEJMoa1515920"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. <i>Diabetes Obes Metab<\/i> 2018; 20: 1988\u20131993.","DOI":"10.1111\/dom.13301"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. <i>J Clin Med Res<\/i> 2016; 8: 844\u2013847.","DOI":"10.14740\/jocmr2760w"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 2013; 15: 853\u2013862.","DOI":"10.1111\/dom.12127"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. O\u2019Neill J, Fasching A, Pihl L, Patinha D, Franzen S, Palm F. Acute SGLT inhibition normalizes O<sub>2<\/sub> tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. <i>Am J Physiol Renal Physiol<\/i> 2015; 309: F227\u2013F234.","DOI":"10.1152\/ajprenal.00689.2014"},{"key":"33","unstructured":"33. Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? <i>Semin Nephrol<\/i> 2012; 32: 452\u2013462."}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/2\/10\/2_CR-20-0041\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T03:27:56Z","timestamp":1602300476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/2\/10\/2_CR-20-0041\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-20-0041","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]}}}